Delayed Obstruction with Asymptomatic Loss of Renal Function after Dextranomer/Hyaluronic Acid Copolymer (Deflux) Injection for Vesicoureteral Reflux: a Close Look at a Disturbing Outcome

Papagiannopoulos, D.; Rosoklija, I.; Cheng, E.; Yerkes, E.

Urology. 2016 Oct 1


Dextranomer/hyaluronic acid copolymer (Deflux) first received FDA approval in 2001 for endoscopic injection in children with grade II-IV vesicoureteral reflux (VUR). As experience has grown, Deflux has been used more liberally with encouraging results. We report three cases where Deflux was used in off-label fashion, resulting in delayed ureteral obstruction and loss of renal function (range 18-52 months post-operatively). We now place increased emphasis on the need for long-term follow-up after Deflux in both routine and complex cases, particularly in situations of off-label use.

Read More on PubMed